Current Report Filing (8-k)
November 05 2019 - 04:12PM
Edgar (US Regulatory)
false 0001590877 0001590877 2019-11-05
2019-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5,
2019
REGENXBIO Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
|
001-37553
|
|
47-1851754
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
9600 Blackwell Road, Suite 210
Rockville, Maryland
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(240) 552-8181
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class
|
Ticker symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par value per share
|
RGNX
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 under the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of
1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 5, 2019, REGENXBIO Inc. (the “Company”) issued a press
release regarding its results of operations and financial condition
for the quarter ended September 30, 2019. The press release is
furnished as Exhibit 99.1 to this Current Report on
Form 8‑K and is incorporated by reference herein.
The information in Item 2.02 of this Current Report on
Form 8‑K and Exhibit 99.1 attached hereto shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to liability under that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
REGENXBIO INC.
|
|
|
|
|
Date: November 5, 2019
|
|
By:
|
|
/s/ Patrick J. Christmas II
|
|
|
|
|
|
Patrick J. Christmas II
|
|
|
|
|
|
Senior Vice President, General Counsel
|
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Dec 2020 to Jan 2021
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Jan 2020 to Jan 2021
